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Findings are inconsistent about whether tobacco, alcohol, and human papillomavirus (HPV) are two independent HNC risk
factor groups that distinguish an infection-associated cancer from a tobacco/alcohol-associated HNC. We found that cancer in the
oral cavity risk was greater in HPV-E6/E7 seropositive/heavy tobacco users (adjusted OR = 3.5) than in HPV-seronegative/heavy
tobacco users (adjusted OR = 1.4); and HPV-seropositive/heavy alcohol users (adjusted OR = 9.8) had greater risk than HPV-
seronegative/heavy alcohol users (adjusted OR = 3.1). In contrast, the risk of oropharyngeal cancer was greater in the HPV-
seronegative/heavy tobacco (adjusted OR = 11.0) than in HPV-seropositive/heavy tobacco (adjusted OR = 4.7) users and greater
in HPV-seronegative/heavy alcohol users (adjusted OR = 24.3) compared to HPV-seropositive/heavy alcohol users (adjusted
OR = 8.5). Disease-speciﬁc and recurrence-free adjusted survival were signiﬁcantly worse in oropharyngeal HPV-seronegative
cases with no survival diﬀerences by HPV status seen in oral cavity cases. The association between tobacco/alcohol, HPV, and
tumor site is complex. There appear to be distinct tumor site diﬀerences in the combined exposure risks, suggesting that diﬀerent
molecular pathways are involved.
1.Introduction
Human papillomavirus (HPV) is now an established risk
factor for head and neck cancers (HNC) [1, 2]. Whether
HPV is an independent risk factor of tobacco and alcohol,
the other two major causes of tumors at these sites, has
not been well clariﬁed [1, 3–5]. It is known that those
who are infected with HPV have signiﬁcantly better survival
[6, 7], thus it would be important to clarify the role of
these risk factors. Many case-control studies traditionally
have employed the anti-VLP-HPV antibody ELISA test to
detectahistoryofHPVinfection.Fewerstudieshaveassessed
the risk of HNC associated with antibodies against HPV
E6/E7 oncoproteins. E6/E7 antibodies are biomarkers of
HPV-associated cancer and possibly precancerous lesions
and as such should provide a more sensitive measure of
HPV-related disease in individuals and in evaluating the
association with or independence from tobacco and alcohol.
The purpose of this study was to examine HPV E6/E7 anti-
body status in patients with oral cavity and oropharyngeal
HNC, and in healthy controls, for diﬀerences in HPV status
associated with tobacco and alcohol use. The study also
evaluated site-speciﬁc HNC survival and recurrence by HPV
E6/E7 antibody status compared to HPV tumor tissue status
associated with tobacco and alcohol.
2.MaterialsandMethods
2.1. Patient Data Collection. Patient characteristics and
exclusions have been described previously [1]. Cases with a2 Journal of Oncology
primary HNC ages 18 and older diagnosed between 2001
and 2004 at the University of Iowa Hospitals, Department of
Otolaryngology and the Iowa City Veterans Administration
Hospital, were eligible for enrollment. All oral cavity (N =
170) and oropharyngeal (N = 74) sites were included. There
were 244 eligible cases enrolled after exclusions. Gender and
5-year age group frequency matched controls (n = 428) were
recruited from clinics in Family Medicine and in Internal
Medicineatthesehospitalswhowereseekingroutinemedical
care.
Patients signed an institutionally approved informed
consent form prior to completing a self-administered
risk factor questionnaire that included information about
sociodemographics, medical history, tobacco and alcohol
use,sexualpractices,andhistoryofHPV-relateddiseasesand
oral lesions. Prior cancer history, head and neck tumor site,
treatments, and staging were collected from medical records
and pathology reports. All tobacco and alcoholic products
were included and equivalents were used [1].
2.2. HPV Laboratory Methods. Ab l o o ds p e c i m e nw a sd r a w n
from participants to detect HPV at the time of diagnosis
prior to cancer treatment for cases or during the interview
for controls. Detection of HPV-speciﬁc antibodies has been
describedpreviously[3–8].TheLuminexproceduredetected
the presence of HPV E6 and E7 and HPV types were
identiﬁed with multiplex serology [9, 10]. Multiplex serology
uses viral L1 proteins expressed in bacteria as glutathione S-
transferase (GST) fusion proteins as antigens [10, 11].
Paraﬃn-embedded tumor tissue was available from 204
casestoevaluateforHPV.Samplepreparation,PCRanalyses,
DNA hybridization, and HPV typing procedures for assess-
mentoftumortissuewerebasedonastandardprotocol[12].
Each PCR reaction included primers to amplify the β-globin
gene [13]a n dv e r i ﬁ e ds u ﬃcient DNA and adequacy of the
PCR ampliﬁcation. Extracted DNA was PCR-ampliﬁed with
MY09/MY11 primers [14] to detect HPV and with primer
HMB01 to better amplify HPV-51 [15]. Positive samples
underwent heminested PCR-ampliﬁcation with MY09 and
GP5+ primers [16]. DNA sequencing was used to determine
the HPV types in each specimen, and sequences were
compared to GenBank sequences using the BLAST program
[17]. High-risk, oncogenic HPV types (HR-HPV) detected
in tumor tissue included HPV-16 and 33.
2.3. Statistics. Odds ratios (OR), 95% conﬁdence intervals
(CI)andP valuesforriskfactors,andpathologiccharacteris-
tics were adjusted for continuous age, gender, tobacco pack-
years, and average drinks per week. Categorical variables
included age, education, number of sexual partners, tobacco
pack-years,andaveragenumberofalcoholicdrinksperweek.
Cut points for moderate and heavy tobacco or alcohol users
were based on the overall distributions or median values
among HPV-negative cases and controls. ORs and CIs were
calculated using multivariate logistic regression analyses. For
variables with zero cells, ORs and CIs were generated using
logit methods, adjusting for categorical age, tobacco, and
alcohol except when limited by small cell sizes.
Individual and joint eﬀects of tobacco and alcohol strat-
iﬁed by HPV status were examined by tumor site and never
users of tobacco or alcohol (reference groups) were com-
pared to moderate or heavy tobacco or alcohol users among
cases and controls. Additive joints eﬀects and 95% CIs were
assessed using the synergy index [18] while multiplicative
interactions were examined by including the appropriate
interaction term in the multivariate logistic regression mod-
els [19]. Survival curves were generated using Kaplan-Meier
methods while Cox proportional hazards models were used
to generate hazard ratios (HR) and 95% conﬁdence intervals
(CI), adjusted for continuous age and stage of disease (I/II
versus III/IV). Nodal involvement, tumor site, and grade
were excluded from models due to their high correlation
with disease stage. Gender, pack-years, and drinks per week
werenotassociatedwithsurvivalorrecurrenceandthuswere
not included in the models. Analyses comparing HPV E6/E7
assays and tumor HPV DNA included only those patients
withresultsfrombothassays(N = 204cases).Sensitivitywas
deﬁned as the percent of HPV DNA positive who were E6/E7
positive; speciﬁcity as the percent of HPV DNA negative
who were E6/E7 negative; and, concordance as the percent
positive for both tests and negative for both tests. Magnitude
of agreement was measure by the Kappa statistic. All P values
weretwosided,andvalues ≤0.05wereconsideredstatistically
signiﬁcant. Statistical analyses were performed using SAS
version 9.2.
3. Results
3.1.RiskFactors. TheprevalenceofHPV-16/18/33 E6and/or
E7 was greater in HNC cases than in controls: 26% versus
7%; it was higher in oropharyngeal cases (64%) compared
to oral cavity cases (9%) or controls (7%; Table 1). HPV-16
was the most frequent type detected in cases and controls
(25%/5%), followed by HPV-33 (15%/2%), and HPV-18
(0.8/0.9%). Almost all cases with HPV-33 also were detected
with HPV-16 (97%) whereas only a third (33%) of controls
were. Those detected with HPV-18 were not detected with
any other HPV type. The frequency of HPV-16 E6 or E7 only
was similar in both cases (20%/18%) and controls (1%/4%).
Compared to HPV-seronegative cases, HPV-seropositive
cases were signiﬁcantly more likely to be male. Those with
tumors in the oropharynx who were HPV E6/E7 seropositive
were more likely to be younger, more educated, and perform
oral-genitalsex(Table 1).Theyalsoshowedhighergradeand
positive nodal status than did tumors in the oral cavity. No
diﬀerences among controls were identiﬁed.
3.2. HPV E6/E7, Tobacco, and Alcohol Status Associated with
Site-Speciﬁc HNC Risk. We next examined the relationship
between tobacco, alcohol, and HPV E6/E7 status by tumor
site (Table 2). Compared to controls, those with cancer
of the oral cavity had a minimal increased risk among
heavy tobacco users whereas the risk of oropharyngeal
cancer was increased in both tobacco dose-duration groups
and higher in heavy users. Parallel ﬁndings were seen for
alcohol use although the risks were twice those seen forJournal of Oncology 3
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Table 2: Site-speciﬁc head and neck cancer associated with tobacco, alcohol, and HPV E6/E7 status.1
Cases Controls Oral Cavity
versus controls
Oropharynx versus
controls
Oral cavity (N = 170) Oropharynx (N = 74) (N = 428) OR2 (95% CI) OR2 (95% CI)
Characteristic N (%) N (%) N (%)
Tobacco
Never 57 (33.7) 10 (13.7) 160 (37.7) 1.0 1.0
≤30 44 (26.0) 25 (34.2) 142 (33.4) 0.9 (0.5–1.4) 2.1 (0.9–5.2)
>30 68 (40.2) 38 (52.1) 123 (28.9) 1.5 (0.9–2.4) 5.6 (2.3–13.7)
Alcohol
Never 60 (35.5) 8 (11.0) 184 (43.2) 1.0 1.0
≤21 59 (34.9) 37 (50.7) 181 (42.5) 1.1 (0.7–1.8) 4.3 (1.7–10.4)
>21 50 (29.6) 28 (38.4) 61 (14.3) 3.6 (2.1–6.2) 11.7 (4.2–32.7)
Tobacco/alcohol
Never/never 42 (25.0) 3 (4.1) 100 (23.6) 1.0 1.0
≤30/≤21 23 (13.7) 14 (19.2) 72 (17.0) 1.0 (0.5–1.8) 5.2 (1.2–21.7)
≤30/>21 10 (6.0) 8 (11.0) 26 (6.1) 1.4 (0.6–3.5) 15.9 (3.2–80.2)
>30/≤21 22 (13.1) 17 (23.3) 55 (13.0) 1.3 (0.6–2.4) 16.6 (3.9–71.4)
>30/>21 39 (23.2) 19 (26.0) 29 (6.9) 5.2 (2.6–10.5) 34.6 (7.5–158.8)
HPV E6/E7 status1
Positive 16 (9.4) 47 (63.5) 31 (7.2) 1.7 (0.9–3.3) 24.3 (12.9–45.8)
Negative3 154 (90.6) 27 (36.5) 397 (92.8) 1.0 1.0
1Percentages based on available data; 2odds ratio adjusted by age (continuous), gender, HPV status, tobacco, and alcohol; 3HPV E6/E7 negative status for all
types, E6/E7 positive status for HPV-16, -18, and/or -33.
tobacco exposures, regardless of tumor site. The adjusted
risk of tumors in the oral cavity did not increase in the
joint heavy tobacco/alcohol users (>30/>21, OR = 5.2)
over heavy tobacco users and heavy alcohol users. There
was no multiplicative eﬀect associated with tobacco/alcohol
among tumors in the oropharynx for heavy users of both,
but there was a signiﬁcant additive eﬀect (OR = 34.6).
The independent risk was signiﬁcantly greater among those
with HPV-seropositive status after controlling for tobacco,
alcohol, and other risk factors but only in tumors of the
oropharynx.
3.3. Site-Speciﬁc HNC Risk Stratiﬁed by HPV, Tobacco, and
Alcohol Status . Based on the distinct ﬁndings by tumor site
fortobaccoandalcoholrisk,datawerenextstratiﬁedbyHPV
E6/E7 status (Table 3). Compared to controls, cases with oral
cavity tumors who were heavy tobacco users had an elevated
risk but only among those who were HPV-seropositive (OR
= 3.5) but not HPV-seronegative. Those with oropharyngeal
cancerhadelevatedrisksatthehighertobaccodose-duration
level as well but in both the HPV-seropositive and HPV-
seronegative groups, with the odds much higher for the
HPV-seronegative group (OR = 11.0 versus 4.7). HPV-
seropositive risk was higher in the oropharynx than found
in the oral cavity. The risk associated with alcohol use was
elevated only in the heaviest users (>21) in oral cavity cases
regardless of HPV E6/E7 status, but was higher in the HPV-
seropositive group (OR = 9.8 versus 3.1). The ORs for the
oropharynxweresigniﬁcantlyelevatedforbothalcohollevels
regardless of HPV E6/E7 status although, in contrast to the
oral cavity, they were higher in the HPV-seronegative cases.
Again there was little diﬀerence in risk between the two
tumor sites among HPV-seropositive heavy users.
When both tobacco and alcohol were examined in
stratiﬁed analyses associated with HPV status, only the heavy
tobacco/alcohol (>30/>21) group was elevated for cancer
of the oral cavity (Table 3). Consistent with the individual
tobacco and alcohol groups, higher risk was particularly seen
inthosewhowereHPVE6/E7seropositive. Again,adiﬀerent
picture was seen for oropharyngeal cancers. Increased risk
was shown for almost all tobacco/alcohol groups compared
to never users of both. Risks were greater among those who
were HPV-seronegative/heavy tobacco/heavy alcohol users
than among those who were HPV-seropositive/heavy users
of both. CIs were wide due to the expected small rate of HPV
E6/E7 positivity in controls.
3.4. Comparison between HPV E6/E7 Serology and HPV
Tumor DNA . There were 145 oral cavity and 59 oropharynx
cases with both serology and tumor tissue assessed for
HPV status. The prevalence of HPV-seropositive in the oral
cavity was 10% and 64% in the oropharynx, and 13%/58%
for oral cavity/oropharynx tumor HPV DNA-positive status
(Table 4). Type-speciﬁc concordance between HPV-positive
tumors (HPV-16 and/or -33) and HPV-seropositivity was
93% (K = 0.9, 0.7–0.99) for the oropharynx and 84% (K
= 0.2, 0.003–0.4) in the oral cavity. The sensitivity of HPV
E6/E7 antibodies to DNA HPV-positive tumors in the oral
cavity was 26% and 100% in the oropharynx.Journal of Oncology 5
Table 3: Site-speciﬁc head and neck cancer stratiﬁed by HPV E6/E7, tobacco, and alcohol status.1
Cases Controls Oral cavity versus
controls
Oropharynx versus
controls
Oral cavity Oropharynx OR (95% CI) OR (95% CI)
HPV E6/E72 Risk factor N = 170 (%) N = 74 (%) N = 428 (%)
Tobacco3
Negative Never 54 (32.0) 2 (2.7) 150 (35.3) 1.0 1.0
≤30 41 (24.3) 6 (8.2) 127 (29.9) 0.9 (0.6–1.5) 3.2 (0.6–16.6)
>30 58 (34.3) 19 (26.0) 119 (28.0) 1.4 (0.8–2.3) 11.0 (2.4–51.7)
test for trend P value 0.19 <0.0001
Positive Never 3 (1.8) 8 (11.0) 10 (2.4) 1.0 1.0
≤30 3 (1.8) 19 (26.0) 15 (3.5) 0.3 (0.03–2.4) 1.4 (0.4–4.9)
>30 10 (5.9) 19 (26.0) 4 (0.9) 3.5 (0.5–26.9) 4.7 (1.03–21.7)
test for trend P value 0.008 0.01
Alcohol4
Negative Never 57 (33.7) 2 (2.7) 170 (39.9) 1.0 1.0
≤21 54 (32.0) 10 (13.7) 166 (39.0) 1.1 (0.7–1.8) 5.4 (1.1–25.7)
>21 42 (24.8) 15 (20.6) 59 (13.9) 3.1 (1.7–5.5) 24.3 (4.9–121.3)
test for trend P value 0.009 <0.0001
Positive Never 3 (1.8) 6 (8.2) 14 (3.3) 1.0 1.0
≤21 5 (3.0) 27 (37.0) 15 (3.5) 1.2 (0.2–7.3) 4.1 (1.2–14.7)
>21 8 (4.7) 13 (17.8) 2 (0.5) 9.8 (0.9–106.9) 8.5 (1.2–60.2)
test for trend P value 0.002 0.001
Tobacco/alcohol5
Negative Never/never 40 (23.8) 1 (1.4) 93 (22.0) 1.0 1.0
≤30/≤21 21 (12.5) 1 (1.4) 63 (14.9) 1.0 (0.5–1.9) 1.9 (0.1–31.1)
≤30/>21 10 (6.0) 4 (5.5) 24 (5.7) 1.5 (0.6–3.6) 22.8 (2.2-235.2)
>30/≤21 20 (11.9) 8 (11.0) 53 (12.5) 1.2 (0.6–2.3) 18.7 (2.2–160.8)
>30/>21 31 (18.4) 11 (15.1) 29 (6.7) 4.0 (2.0–8.3) 56.3 (6.2–512.7)
test for trend P value 0.07 <0.0001
Positive Never/never 2 (1.2) 2 (2.7) 7 (1.7) 1.0 1.0
≤30/≤21 2 (1.2) 13 (17.8) 9 (2.1) 0.7 (0.04–12.0) 8.9 (0.96–82.9)7
≤30/>21 0 (0.0) 4 (5.5) 2 (0.5) 0.6 (0.02–17.2)6 13.7 (0.8–227.9)
>30/≤21 2 (1.2) 9 (12.3) 2 (0.5) 2.6 (0.1–67.4) 29.3 (2.1–408.7)7
>30/>21 8 (4.8) 8 (11.0) 0 (0.0) 55.0 (0.8–3651.0)6,7 18.3 (0.5–627.2)6,7
test for trend P-value 0.008 0.001
1Percentages based on available data; 2HPV E6/E7 seronegative for HPV-16, -18, and/or -33; HPV E6/E7 seropositive for HPV-16, -18, and/or -33; 3adjusted
for age (continuous), gender, and average drinks/week (continuous); 4adjusted for age (continuous), gender, and tobacco pack-years (continuous); 5adjusted
for age (continuous) and gender, all never groups combined with never/never as reference group; 6Logit estimator, 0.5 is added to zero cells; 7CMH P-value
< 0.049.
Moderate smokers (compared to never or to heavy
smokers) had elevated ORs for both HPV-seropositive and
tumorHPVDNA-positivecomparedtoHPV-negativestatus.
Both moderate and heavy alcohol users had elevated ORs
compared to never drinkers for either HPV assessment.
For the joint eﬀects of alcohol and tobacco, moderate
smokers/drinkers (≤30/≤21) and moderate smokers/heavy
drinkers (≤30/≥21) had the greatest odds of being HPV-
positive; other risks were similar for serology and tumor
tissue. Sample sizes were insuﬃcient to evaluate risk factors
for HPV serology and DNA by tumor site.
3.5. Survival and Recurrence Associated with HPV E6/E7 and
Tumor DNA Status. Table 5 displays the HRs for disease-
speciﬁcsurvival(DSS)andrecurrence-freesurvival(RFS)for
newly diagnosed patients with survival information (DSS =
144;RFS =127).AlsoshownisacomparisonofDSSandRFS
between HPV tumor and serology among newly diagnosed
cases with HPV results available for both outcomes (N =
157). Among those who did not survive, 56% died from
HNC, 28% from other causes and 16% had an unknown
cause. A ﬁrst recurrence occurred in 30% of all patients.
Median follow-up time for DSS was 5.3 years (range: 16 Journal of Oncology
Table 4: Tobacco and alcohol status in head and neck cancer cases by HPV E6/E71,2 and tumor HPV status1 (N = 204).
Risk factor E6/E7 positive E6/E7 negative OR (95% CI) Tumor positive3 Tumor negative3
OR (95% CI)
N (%) N (%) N (%) N (%)
Prevalence 52 (25.5) 152 (74.5) 53 (26.0) 151 (74.0)
Tumor site
Oral cavity 14 (26.9) 131 (86.2) 1.0 19 (35.9) 126 (83.4) 1.0
Oropharynx 38 (73.1) 21 (13.8) 17.3 (7.4–40.5) 34 (64.2) 25 (16.6) 8.8 (4.1–19.0)
Tobacco4
Never 8 (15.7) 49 (32.5) 1.0 9 (17.3) 48 (32.0) 1.0
≤30 20 (39.2) 37 (24.5) 2.1 (0.8–5.7) 23 (44.2) 34 (22.7) 3.0 (1.2–7.5)
>30 23 (45.1) 65 (43.0) 1.1 (0.4–3.1) 20 (38.5) 68 (45.3) 1.2 (0.5–3.4)
≤30 versus >30 1.9 (0.8–4.2) 2.3 (1.1–5.1)
Alcohol5
Never 7 (13.7) 51 (33.6) 1.0 8 (15.4) 50 (33.1) 1.0
≤21 24 (47.1) 56 (36.8) 2.3 (0.8–6.2) 27 (51.9) 53 (35.1) 3.0 (1.2–7.8)
>21 20 (39.2) 45 (29.6) 2.1 (0.7–6.4) 17 (32.7) 48 (31.8) 2.2 (0.7–6.8)
≤21 versus >21 1.1 (0.5–2.5) 3 (5.8) 10 (6.7) 1.3 (0.6–3.0)
Tobacco/alcohol6
Never//never 4 (7.8) 38 (25.2) 1.0 1.0
≤30/≤21 13 (25.5) 21 (13.9) 3.2 (0.9–12.0) 15 (28.9) 19 (12.7) 4.2 (1.2–14.0)
≤30/>21 4 (7.8) 10 (6.6) 1.8 (0.3–9.3) 5 (9.6) 9 (6.0) 2.6 (0.6–11.8)
>30/≤21 8 (15.7) 24 (15.9) 1.6 (0.4–6.7) 9 (17.3) 23 (15.3) 1.9 (0.5–6.8)
>30/>21 15 (29.4) 34 (22.5) 1.6 (0.4–5.9) 11 (21.2) 38 (25.3) 1.2 (0.3–4.2)
1Percentages based on available data; 2HPV E6/E7 seronegative for HPV-16, and -33; HPV E6/E7 seropositive for HPV-16 and/or -33; 3DNA negative
for all HPV DNA types; DNA positive for HPV-16 and/or -33; 4adjusted for age (continuous), gender, tumor site (oral cavity, oropharynx), and average
drinks/week (continuous); 5adjusted for age (continuous), gender, tumor site (oral cavity, oropharynx), and tobacco pack-years (continuous); 6adjusted for
age (continuous) and gender.
Table 5: Adjusted1 hazard ratios for disease-speciﬁc and recurrence free survival.2
Risk Factors
Oral cavity Oropharynx
Disease-speciﬁc Survival1 Recurrence-free survival1 Disease-speciﬁc survival1 Recurrence-free survival1
HR (95% CI) HR (95% CI) HR (95% CI) HR (95% CI)
Patients with HPV serology (N = 182)
N = 116 N = 96 N = 52 N = 43
E6 and/or E7 nn n n
Negative 103 (88.8) 1.3 (0.4–4.2) 86 (89.6) 1.1 (0.3–3.6) 16 (30.8) 5.7 (1.7–20.0) 13 (30.2) 6.7 (1.7–26.1)
Positive 13 (11.2) 1.0 10 (10.4) 1.0 36 (69.2) 1.0 30 (69.8) 1.0
Age2 1.02 (1.0–1.1) 1.02 (1.0–1.04) 1.04 (0.96–1.1) 1.03 (0.95–1.1)
Stage
0/I/II 1.0 1.0 1.0 1.0
III/IV 7.9 (2.8–22.5) 1.5 (0.7–3.1) 1.5 (0.2–11.4)3 1.3 (0.03–58.8)
Patients with both HPV tumor and serology (N = 157)
N = 100 N = 88 N = 44 N = 39
E6 and/or E7 nn n n
Negative 89 (89.0) 1.4 (0.4–4.5) 80 (90.9) 1.1 (0.3–3.5) 14 (31.8) 4.2 (1.2–15.1) 12 (30.8) 10.4 (2.4–52.4)
Positive 11 (11.0) 1.0 8 (9.1) 1.0 30 (68.2) 1.0 27 (69.2) 1.0
HPV tumor
status
Negative 88 (88.0) 0.8 (0.3–2.0) 78 (88.6) 0.5 (0.2–1.3) 17 (38.6) 3.0 (0.9–10.7) 15 (38.5) 7.3 (1.5–36.4)
High Risk 12 (12.0) 1.0 10 (11.4) 1.0 27 (61.4) 1.0 24 (61.5) 1.0
1Adjusted for stage and continuous age; 2in years; 3odds ratio Logit estimator adjusted for stage and categorical age.Journal of Oncology 7
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Figure 1: (a) Oral cavity disease-speciﬁc Kaplan-Meier survival curves by E6/E7 and tumor DNA status. (b) Oropharynx disease-speciﬁc
Kaplan-Meier survival curves by E6/E7 and tumor DNA status.
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Figure 2:(a)Oralcavityrecurrence-freespeciﬁcKaplan-MeiersurvivalcurvesbyE6/E7andtumorDNAstatus.(b)Oropharynxrecurrence-
free speciﬁc Kaplan-Meier survival curves by E6/E7 and tumor DNA status.
month–10.4 years). Among those who had a DS death, 76%
died within 2 years of diagnosis. The median follow-up time
for RFS was 5.6 years (range: 2 months–10.4 years). For
patients with a ﬁrst recurrence, 76% occurred within 2 years
of diagnosis. Time to recurrence did not signiﬁcantly vary by
HPV E6/E7 status for either site.
HPV status was not signiﬁcantly related to DSS or RFS
for oral cavity cancers (Table 5, Figures 1(a) and 2(a)).
In contrast, oropharyngeal cancer cases who were HPV-
seronegative or DNA-negative reported signiﬁcantly lower
DSS and RFS compared to HPV-positive cases (Table 5,
Figures 1(b) and 2(b)). In a DSS model with tumor site, age,
stage,alcohol,andtobacco,onlyage,higherstage,andtumor
site were signiﬁcant predictors of higher mortality risk (oral
cavity versus oropharynx: HR = 2.1, 1.03–4.4).
Concordance between the HPV tests for both sites
combined was high for DSS and RFS (88%/88%, K = 0.7
both). An examination of sensitivity and speciﬁcity for HPV
E6/E7antibodiesforHPVDNAstatusandsurvivaloutcomes
showed that HPV E6/E7 seronegative status was a strong
indicator of DSS and RFS in tumor DNA HPV-negative
tumors of the oral cavity (DSS/RFS censored: 90%/94%;
death/recurrence: 97%/85%). However, there was weaker
sensitivity between HPV-seropositive and HPV DNA-
positive outcomes (DSS/RFS censored: 33%/20%; death/
recurrence: 33%/67%). In the oropharynx, serology was a
much stronger overall indicator and demonstrated strong
sensitivity and speciﬁcity for tumor tissue status and sur-
vival (HPV-negative DSS/RFS censored: 73%/100%; death/
recurrence: 100%/100%; HPV-positive DSS/RFS censored:
100%/88%; death/recurrence: 100%/100%; Figures 1 and 2).
4. Discussion
The results of this investigation demonstrate that HPV,
tobacco, and alcohol represent three independent risk factors
for HNC in both the oral cavity and oropharynx. Some8 Journal of Oncology
previous studies have suggested [3, 4] that HNC would fall
into two distinct tumor groups with separate risk factors,
HPV or tobacco/alcohol use. Here we show that each risk
factor exerted a signiﬁcant and independent eﬀect by tumor
site,althoughtherisksassociatedwithoropharyngealcancers
were consistently higher than that for the oral cavity. This
ﬁnding is similar to our previous study based on HPV
VLP antibody assessment [1], a lifetime indicator of HPV
infection. In this study, we evaluated HPV E6/E7 antibodies,
a measure of HPV-related current or possibly, precursor
cancer lesions. Other investigations have assessed HNC or
oropharyngeal tumors and also have shown an independent
eﬀect of each of these exposures [5, 20]b a s e do nH P VV L P
antibodies.
The current study is one of the few to also examine these
riskfactorsseparatelyforcancersoftheoralcavity.Intheoral
cavity, the risk was more likely to be elevated among HPV-
positive/higher tobacco and alcohol level users compared to
controls whereas in the oropharynx the opposite was found
with HPV-negative/higher tobacco and alcohol level users
having a greater risk than the seropositive cases. Although
these trends are consistent with our previous investigation
based on VLPs, the risks are higher and more evident with
the HPV E6/E7 antibodies. Unlike Hafkamp et al. [21]b u t
consistent with Fakhry et al. [22], we found that HPV-
positive tumors in never and ever smokers to be unrelated
to DSS or RFS (data not shown). Additionally, we found no
relationship in HPV-positive or -negative cases and alcohol
use. Although the INHANCE analyses did not examine HPV,
greater dose and duration of the independent eﬀects of
tobacco and alcohol use were associated with higher risk in
the oropharynx than in the oral cavity [23].
This also is one of the ﬁrst studies to examine concor-
dance and sensitivity between E6/E7 serology and tumor
DNA for both tumor subsites. We found that they were
higher in the oropharynx than in the oral cavity (concor-
dance: 93%/84%; sensitivity: 89%/36%). Previously, Herrero
et al. [5] reported better although somewhat lower concor-
dance between HPV E6/E7 serology and tumor HPV DNA
in the oropharynx than in the oral cavity: 65% versus 13%.
Their corresponding sensitivity was better in the oropharynx
than oral cavity as well: 64% versus 14% (K = 0.6/K = 0.08).
The higher percentages in our study associated with the oral
cavity may be due to our use of laser microdissection which
is more critical for tumors at this subsite.
It is unclear why site-speciﬁc HPV E6/E7 serol-
ogy/DNA tumor concordance was consistently high for
survival outcomes with the exception of the HPV E6/E7-
seropositive/DNA-positive cancers in the oral cavity. Other
studies of HPV status in association with HNC survival have
focused on oropharyngeal cancer and none has reported on
the sensitivity of HPV serology associated with tumor DNA
and clinical outcomes [3]. This assessment showed that not
only is DS survival better in HPV-positive oropharyngeal
cases than in HPV-positive oral cavity cases, but also that
they have better RFS than in the oral cavity. Rotn´ aglov´ a
et al. [24] also have shown that DSS is signiﬁcantly better
in HPV E6/E7 seropositive or tumor DNA-positive tonsillar
cases followed an average four years, although they did not
compare cases with both measures of HPV status.
This investigation suggests that while risk of HNC by
t u m o rs i t ei sb o t hd i ﬀerent between oral cavity and orophar-
ynx, both sites are nonetheless associated with independent
eﬀects for each of the three major HNC risk factors. The
combined eﬀects alter HNC risk diﬀerently in a comparison
of HPV-negative versus HPV-positive cases in the oral cavity
and the oropharynx. Further, patients with oropharyngeal
tumors are diﬀerent from oral cavity cases not only for the
three risk factors but also because they are younger in age,
have higher prevalence of heavy tobaccoand alcohol use, and
are diagnosed at a later stage and with nodal involvement.
It is not clear how these diﬀerences explain the distinctly
diﬀerent survival and recurrence outcomes found. Addi-
tional studies are need that examine HPV in the presence
or absence of tobacco and alcohol to evaluate diﬀerences in
chromosomal alterations and molecular pathways to clarify
these risk and survival diﬀerences by tumor site.
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